This article is more than 5 years old. Information may no longer be current.
Childhood HSCT increased risk for kidney stones
Click Here to Manage Email Alerts
Patients who received hematopoietic stem cell transplantation as part of childhood cancer treatment exhibited an increased risk of developing kidney stones as adults, according to results of a retrospective study.
Kidney stones are known to develop in patients treated for childhood cancer, but previous studies have not established the association in children who undergo hematopoietic stem cell transplantation (HSCT).
To determine risk factors for the development of kidney stones and to illustrate its prevalence among HSCT survivors, researchers examined 1,343 children who underwent HSCT. Of them, 360 received a long course of methotrexate for acute graft-versus-host disease prophylaxis, 626 received a short course and 357 received none.
The researchers used multivariate Cox regression models to assess the HR of risk factors associated with kidney stones.
Fifty-one patients developed kidney stones. They developed a median 9.9 years (range, 0.2-29.4) after first HSCT. Researchers reported a 30-year cumulative incidence of 7.4%.
Risk factors associated with kidney stones were total body irradiation (HR=2.2; P=.03), age at HSCT (12-18 years vs. <6 years, HR=2.7; P=.01), methotrexate treatment (long course vs. none, HR=3.6; P=.02) and prednisone (HR=2.2; P=.008).
Among 868 HSCT survivors, the prevalence of a history of kidney stones was 4.7%.
Disclosure: The researchers report no relevant financial disclosures.
Collapse
Click Here to Manage Email Alerts